All In Biotech

Drug Trial Radar · NCT03325790

SPI-1005 for the Treatment of Patients With Meniere's Disease

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease

Last checked: Nov 19, 2026Latest source record: Sep 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Sep 28, 2017

Primary completion

Apr 30, 2019

Study completion Apr 30, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.

Conditions

  • Meniere's Disease

Interventions

  • 200mg SPI-1005 BIDDrug

    Active: low dose

  • 400mg SPI-1005 BIDDrug

    Active: high dose

  • PlaceboOther

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: 8 weeks
  2. Efficacy of SPI-1005 on Hearing LossTime frame: 8 weeks
  3. Efficacy of SPI-1005 on Word Recognition ScoreTime frame: 8 weeks
  4. Efficacy of SPI-1005 on TinnitusTime frame: 8 weeks
  5. Efficacy of SPI-1005 on Tinnitus LoudnessTime frame: 8 weeks
  6. Efficacy of SPI-1005 on VertigoTime frame: 8 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Ccent/Cccr

    Fresno, California

  • UCSD

    San Diego, California

  • UCSF

    San Francisco, California

  • Georgetown University

    Washington D.C., District of Columbia

  • UMiami

    Miami, Florida

  • KUMC

    Kansas City, Kansas

  • Advanced ENT & Allergy

    Louisville, Kentucky

  • ENT and Allergy Associates, LLP

    New York, New York

  • CEENTA

    Charlotte, North Carolina

  • TJU

    Philadelphia, Pennsylvania

  • MUSC

    Charleston, South Carolina

  • UT Southwestern

    Dallas, Texas

  • Northwest Ear, Inc.

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.